ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
Rhea-AI Summary
ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. President and CEO Donn Casale will outline updated strategic priorities and report second quarter 2026 financial results. Dial-in details require event registration, while webcast access and slides will be available via the company’s website, with a replay accessible for 30 days.
Positive
- None.
Negative
- None.
Market reaction after 2Q26 earnings report: SPRY -8.25%
Following this news, SPRY has declined 8.25%, reflecting a notable negative market reaction. Our momentum scanner has triggered 6 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $4.95.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 earnings call | Neutral | -3.0% | Scheduled discussion of first-quarter results and business highlights |
| Feb 23 | Q4 earnings call | Neutral | +2.3% | Scheduled fourth-quarter and full-year results discussion |
| Nov 03 | Q3 earnings call | Neutral | -3.8% | Scheduled third-quarter results and business highlights discussion |
| Aug 04 | Q2 earnings call | Neutral | +1.2% | Scheduled discussion of second-quarter results and business highlights |
| May 05 | Q1 earnings call | Neutral | -1.4% | Scheduled first-quarter results and business highlights discussion |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Comparable conference-and-earnings announcements produced mixed 24-hour reactions, with three declines and two gains, averaging -0.94%.
Key Terms
anaphylaxis medical
epinephrine medical
idiopathic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. During the call, Donn Casale, President and Chief Executive Officer, will outline the Company’s updated strategic priorities and report second quarter 2026 financial results.
Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company’s website. A replay of the webcast will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU and 优敏速® in China), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
ARS Investor Contact:
Monique Allaire, THRUST
monique@thrustsc.com
ARS Media Contact:
Christy Curran, Sam Brown Inc.
615.414.8668
christycurran@sambrown.com
